Mineralocorticoid Receptor Blockade in Chronic Kidney Disease

被引：20

作者：

Volk, Matthew J. ^{[2
]}

Bomback, Andrew S. ^{[3
]}

Klemmer, Philip J. ^{[1
]}

机构：

[1] Univ N Carolina, UNC Kidney Ctr, Chapel Hill, NC 27514 USA

[2] Univ N Carolina, Dept Med, Div Nephrol & Hypertens, Chapel Hill, NC 27514 USA

[3] Columbia Univ, Dept Med, Div Nephrol, Coll Phys & Surg, New York, NY USA

来源：

CURRENT HYPERTENSION REPORTS | 2011年 / 13卷 / 04期

关键词：

Aldosterone; Aldosterone breakthrough; Mineralocorticoid blockade; Chronic kidney disease; CKD; Extracellular volume; Bioimpedance; Tissue inflammation; Hyperkalemia; Hypertension; ANGIOTENSIN-ALDOSTERONE SYSTEM; METABOLIC SYNDROME; PERITONEAL-DIALYSIS; BLOOD-PRESSURE; RESISTANT HYPERTENSION; ALDACTONE THERAPY; DIETARY-SODIUM; RENAL-DISEASE; UP-REGULATION; SLEEP-APNEA;

D O I：

10.1007/s11906-011-0202-2

中图分类号：

R6 [外科学];

学科分类号：

1002 ; 100210 ;

摘要：

Aldosterone antagonists have been highly successful in treating congestive heart failure and resistant hypertension. Until recently, therapies targeting the mineralocorticoid receptor in chronic kidney disease (CKD) have received little attention, largely because of the risk of hyperkalemia and the incorrect assumption that traditional therapy with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, or both consistently reduces activity of the renin-angiotensin system in all patients. Control of extracellular volume and low-dose mineralocorticoid receptor blocker therapy may offer additional antihypertensive and anti-inflammatory benefits in select CKD populations.

引用

页码：282 / 288

页数：7

共 50 条

[21] Endogenous bufadienolides, mineralocorticoid receptor antagonists and fibrosis in chronic kidney disease
Rosenberg, Mai
Bagrov, Alexei Y.
[J]. FRONTIERS IN PHARMACOLOGY, 2024, 15
[22] Finerenone: a new mineralocorticoid receptor antagonist to beat chronic kidney disease
Raj, Rajesh
[J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2022, 31 (03): : 265 - 271
[23] MINERALOCORTICOID RECEPTOR BLOCKADE IN CHILDREN WITH CHRONIC ALLOGRAFT INJURY
Medeiros, Mara
Velasquez-Jones, Luis
Maria Hernandez, Ana
Valverde, Saul
Fuentes, Yolanda
Barrera-Chimal, Johnatan
Perez-Villalba, Rosalba
Bobadilla-Sandoval, Norma
[J]. PEDIATRIC TRANSPLANTATION, 2013, 17 : 71 - 71
[24] Mineralocorticoid antagonists in chronic kidney disease
Al Dhaybi, Omar
Bakris, George
[J]. CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2017, 26 (01): : 50 - 55
[25] MINERALOCORTICOID RECEPTOR BLOCKADE IN CHRONIC HEART-FAILURE
STRUTHERS, AD
[J]. JOURNAL OF HUMAN HYPERTENSION, 1995, 9 (06) : 443 - 446
[26] Potential Role of Mineralocorticoid Receptor Antagonists in Nondiabetic Chronic Kidney Disease and Glomerular Disease
Zachariah, Teena
Radhakrishnan, Jai
[J]. CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2024,
[27] Mineralocorticoid receptor blockade-a novel approach to fight hyperkalaemia in chronic kidney disease (vol 6, pg 464, 2013)
Ritz, Eberhard
Pitt, Bertram
[J]. CLINICAL KIDNEY JOURNAL, 2013, 6 (06): : 674 - 674
[28] Efficacy and safety assessment of mineralocorticoid receptor antagonists in patients with chronic kidney disease
Ding, Kaiyue
Li, Zhuoyu
Lu, Yingying
Sun, Lin
[J]. EUROPEAN JOURNAL OF INTERNAL MEDICINE, 2023, 115 : 114 - 127
[29] Effects of Chronic Kidney Disease on Nanomechanics of the Endothelial Glycocalyx Are Mediated by the Mineralocorticoid Receptor
Fels, Benedikt
Beyer, Arne
Cazana-Perez, Violeta
Giraldez, Teresa
Navarro-Gonzalez, Juan F.
de la Rosa, Diego Alvarez
Schaefer, Franz
Bayazit, Aysun K.
Obrycki, Lukasz
Ranchin, Bruno
Holle, Johannes
Querfeld, Uwe
Kusche-Vihrog, Kristina
[J]. INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (18)
[30] Mineralocorticoid receptor antagonism improves diastolic dysfunction in chronic kidney disease in mice
Bonnard, Benjamin
Pieronne-Deperrois, Marie
Djerada, Zoubir
Elmoghrabi, Soumaya
Kolkhof, Peter
Ouvrard-Pascaud, Antoine
Mulder, Paul
Jaisser, Frederic
Messaoudi, Smail
[J]. JOURNAL OF MOLECULAR AND CELLULAR CARDIOLOGY, 2018, 121 : 124 - 133

← 1 2 3 4 5 →